While Northwestern swims like Scrooge McDuck in its $700 million Lyrica payment, Sloan-Kettering Institute for cancer research is suing Amgen for underpaying royalties by more than $72 million. The cancer center claims that, when calculating royalties, Amgen deducted Aranesp-related rebates from Neupogen and Neulasta sales. The latter two drugs sold at a rate of $1.1 billion just in the third quarter. Amgen denies the claims.
Northwestern sells Lyrica rights for $700M. Report
Lyrica OK'd for epilepsy. Report